Relationships between mucinous gastric carcinoma, MUC2 expression and survival

Figure 1 Expression of the secreted gel-forming mucins in gastric cancers. A: Mucinous subtype in WHO classification, group II in Goseki’s classification (HE-safron × 125); B: Strong MUC2 in mucinous subtype ( in situ hybridization × 40); C: MUC2 in intracellular mucus vacuoles in mucinous subtype (SABC × 125); D: MUC5AC in the cytoplasm of tumoral cells in mucinous subtype (SABC × 125); E: MUC5B in the cytoplasm, within intracellular mucus vacuoles and in extracellular mucus in mucinous subtype (SABC  × 125); F: MUC6 in the cytoplasm of tumoral cells in mucinous subtype (SABC × 200); G: Gastric cancer classified group I in Goseki’s classification (HE-safron ×  125); H: Gastric cancer classified group III in Goseki’s classification (HE-safron, × 200); I: Gastric cancer classified group IV in Goseki’s classification (PAS and Alcian blue ×  200); J: MUC2 in the cytoplasm of tumoral cells in group I gastric cancer Goseki’s classification (SABC × 200); K: MUC2 in intracellular mucus vacuoles in group III gastric cancer in Goseki’s classification (SABC × 200); L: MUC2 in intracellular mucus vacuoles in group IV gastric cancer in Goseki’s classification (SABC × 200).

Figure 2 Survival curves for patients divided according to their Goseki classification.

Figure 3 Survival curves for patients divided according to their immunohistochemical MUC2 expression.